Brief Description
The REBOOT study is a randomized, double-blind, placebo-controlled, phase II, multicenter study for adults with primary membranous nephropathy). REBOOT will investigate whether belimumab, when combined with rituximab, will be a more effective treatment for primary membranous nephropathy than rituximab alone. Participants will receive one year of study treatment and then be followed for another 2 years to assess the impact of the study treatment.
Estimated Enrollment
58
Estimated End Date
12/31/2026
Trial is for people with
Primary Membranous Nephropathy
Study Goal
REBOOT’s primary objective is to determine the effectiveness of the combined treatment with belimumab with rituximab at inducing a ...
What is involved for the patient?
In this study, participants are randomized 3:1 to receive belimumab or belimumab placebo. Participants randomized to receive belimumab ...
About the drug or intervention
B cells are an important component of the immune system and contribute to the development of primary membranous nephropathy. ...